Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice

被引:231
作者
Thurman, JM
Ljubanovic, D
Edelstein, CL
Gilkeson, GS
Holers, VM
机构
[1] Univ Colorado, Hlth Sci Ctr, Div Rheumatol, Denver, CO 80262 USA
[2] Univ Colorado, Hlth Sci Ctr, Div Nephrol & Hypertens, Denver, CO 80262 USA
[3] Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA
[4] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA
[5] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC 29425 USA
关键词
D O I
10.4049/jimmunol.170.3.1517
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Ischemia/reperfusion (I/R) injury of the kidney is a common cause of acute renal failure (ARF) and is associated with high morbidity and mortality in the intensive care unit. The mechanisms underlying I/R injury are complex. Studies have shown that complement activation contributes to the pathogenesis of I/R injury in the kidney, but the exact mechanisms of complement activation have not been defined. We hypothesized that complement activation in this setting occurs via the alternative pathway and that mice deficient in complement factor B, an essential component of the alternative pathway, would be protected from ischemic ARE Wild-type mice suffered from a decline in renal function and had significant tubular injury, particularly in the outer medulla, after I/R. We found that factor B-deficient mice (fB(-/-)) developed substantially less functional and morphologic renal injury after I/R. Furthermore, control wild-type mice had an increase in tubulointerstitial complement C3 deposition and neutrophil infiltration in the outer medulla after I/R, whereas fB(-/-) mice demonstrated virtually no C3 deposition or neutrophil infiltration. Our results demonstrate that complement activation in the kidney after I/R occurs exclusively via the alternative pathway, and that selective inhibition of this pathway provides protection to the kidneys from ischemic ARF.
引用
收藏
页码:1517 / 1523
页数:7
相关论文
共 35 条
[1]  
[Anonymous], 1998, HUMAN COMPLEMENT SYS
[2]  
DENSEN P, 1996, MOL IMMUNOL, V33, P68
[3]   The nature of renal cell injury [J].
Edelstein, CL ;
Ling, H ;
Schrier, RW .
KIDNEY INTERNATIONAL, 1997, 51 (05) :1341-1351
[4]  
Ember J., 1998, The Human Complement System in Health and Disease, P241
[5]   INFECTIOUS-DISEASES ASSOCIATED WITH COMPLEMENT DEFICIENCIES [J].
FIGUEROA, JE ;
DENSEN, P .
CLINICAL MICROBIOLOGY REVIEWS, 1991, 4 (03) :359-395
[6]   C5A-INDUCED EXPRESSION OF P-SELECTIN IN ENDOTHELIAL-CELLS [J].
FOREMAN, KE ;
VAPORCIYAN, AA ;
BONISH, BK ;
JONES, ML ;
JOHNSON, KJ ;
GLOVSKY, MM ;
EDDY, SM ;
WARD, PA .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (03) :1147-1155
[7]   COOPERATIVE INTERACTION OF FACTOR-B AND OTHER COMPLEMENT COMPONENTS WITH MONONUCLEAR-CELLS IN THE ANTIBODY-INDEPENDENT LYSIS OF XENOGENEIC ERYTHROCYTES [J].
HALL, RE ;
BLAESE, RM ;
DAVIS, AE ;
DECKER, JM ;
TACK, BF ;
COLTEN, HR ;
MUCHMORE, AV .
JOURNAL OF EXPERIMENTAL MEDICINE, 1982, 156 (03) :834-843
[8]  
Johnson J P, 1995, New Horiz, V3, P608
[9]   Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury [J].
Kelly, KJ ;
Williams, WW ;
Colvin, RB ;
Meehan, SM ;
Springer, TA ;
GutierrezRamos, JC ;
Bonventre, JV .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (04) :1056-1063
[10]  
KILGORE KS, 1995, J IMMUNOL, V155, P1434